 LAVAL, QC and CAMBRIDGE, England, July 9, 2021 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company, a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. Kedrion the First Closing. 